ReviewCurrent opinion in drug discovery & development2010
Site-specific gene therapy for cardiovascular disease.
Review in Current opinion in drug discovery & development, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy.Journal of thoracic disease · 2018Review
- Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases.Genes & diseases · 2017Review
- Controlling the surface-mediated release of DNA using 'mixed multilayers'.Bioengineering & translational medicine · 2016Article
- Stem cells: An eventual treatment option for heart diseases.World journal of stem cells · 2015Review
- A sight on the current nanoparticle-based gene delivery vectors.Nanoscale research letters · 2014Article
- Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.Cardiovascular ultrasound · 2013Review
- Gene delivery technologies for cardiac applications.Gene therapy · 2012Review
- Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery.Pharmaceutical research · 2012Article
- Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis.Methodist DeBakey cardiovascular journal · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gene therapy holds considerable promise for the treatment of cardiovascular disease and may provide novel therapeutic solutions for both genetic disorders and acquired pathophysiologies such as arteriosclerosis, heart failure and arrhythmias. Recombinant DNA technology and the sequencing of the human genome have made a plethora of candidate therapeutic genes available for cardiovascular diseases. However, progress in the field of gene therapy for cardiovascular disease has been modest; one of the key reasons for this limited progress is the lack of gene delivery systems for localizing gene therapy to specific sites to optimize transgene expression and efficacy. This review summarizes progress made toward the site-specific delivery of cardiovascular gene therapy and highlights selected promising novel approaches.
Indexed as
Identifiers
20205054PMC2845151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.